

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,578	91.7%	20,563	92.2%	1,912	88.3%	1,824	90.3%	116	92.8%	2,859	87.3%
Epidermoid carcinoma ^d (8051-8131)	191	0.7%	149	0.7%	18	0.8%	21	1.0%	-	-	28	0.9%
Adenocarcinoma ^e	22,524	84.0%	18,946	84.9%	1,650	76.2%	1,680	83.1%	105	84.0%	2,560	78.1%
Adenocarcinoma, NOS (8140)	3,291	12.3%	2,679	12.0%	403	18.6%	183	9.1%	-	-	323	9.9%
Papillary adenocarcinoma, NOS (8050,8260)	404	1.5%	350	1.6%	34	1.6%	-	-	-	-	47	1.4%
Clear cell adenocarcinoma (8310,9110)	1,407	5.2%	1,089	4.9%	51	2.4%	257	12.7%	-	-	146	4.5%
Endometrioid carcinoma (8380-8383,8570)	2,593	9.7%	2,186	9.8%	121	5.6%	245	12.1%	-	-	353	10.8%
Cystadenocarcinoma, NOS (8440,8450)	110	0.4%	88	0.4%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	5,601	20.9%	4,798	21.5%	383	17.7%	346	17.1%	35	28.0%	593	18.1%
Papillary serous cystadenocarcinoma (8460-8462)	6,307	23.5%	5,435	24.4%	463	21.4%	357	17.7%	30	24.0%	699	21.3%
Mucinous cystadenocarcinoma (8470-8473)	403	1.5%	332	1.5%	29	1.3%	35	1.7%	-	-	66	2.0%
Mucinous adenocarcinoma (8480,8482)	949	3.5%	756	3.4%	80	3.7%	101	5.0%	-	-	137	4.2%
Mucin-producing adenocarcinoma(8481)	48	0.2%	39	0.2%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,411	5.3%	1,194	5.4%	64	3.0%	133	6.6%	-	-	174	5.3%
Other specific carcinomas ^g	617	2.3%	448	2.0%	120	5.5%	37	1.8%	-	-	103	3.1%
Stromal cell tumor (8620-8631,8650)	425	1.6%	294	1.3%	97	4.5%	22	1.1%	-	-	70	2.1%
Other ^h	192	0.7%	154	0.7%	23	1.1%	-	-	-	-	33	1.0%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,246	4.6%	1,020	4.6%	124	5.7%	86	4.3%	-	-	168	5.1%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	96	0.4%	66	0.3%	20	0.9%	-	-	-	-	20	0.6%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,852	6.9%	1,452	6.5%	204	9.4%	168	8.3%	-	-	361	11.0%
Mullerian mixed tumor (8950-8951,8980)	806	3.0%	674	3.0%	73	3.4%	49	2.4%	-	-	65	2.0%
Teratoma, malignant (9080-9085,9102)	411	1.5%	296	1.3%	54	2.5%	54	2.7%	-	-	146	4.5%
Other	635	2.4%	482	2.2%	77	3.6%	65	3.2%	-	-	150	4.6%
Unspecified (8000-8005)	286	1.1%	232	1.0%	29	1.3%	19	0.9%	-	-	36	1.1%
Total ^d	26,812	100.0%	22,313	100.0%	2,165	100.0%	2,021	100.0%	125	100.0%	3,276	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.